全文获取类型
收费全文 | 3507篇 |
免费 | 230篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 65篇 |
妇产科学 | 27篇 |
基础医学 | 499篇 |
口腔科学 | 62篇 |
临床医学 | 330篇 |
内科学 | 754篇 |
皮肤病学 | 110篇 |
神经病学 | 494篇 |
特种医学 | 139篇 |
外科学 | 586篇 |
综合类 | 32篇 |
预防医学 | 113篇 |
眼科学 | 83篇 |
药学 | 216篇 |
中国医学 | 7篇 |
肿瘤学 | 225篇 |
出版年
2023年 | 22篇 |
2022年 | 41篇 |
2021年 | 72篇 |
2020年 | 63篇 |
2019年 | 75篇 |
2018年 | 96篇 |
2017年 | 59篇 |
2016年 | 91篇 |
2015年 | 99篇 |
2014年 | 126篇 |
2013年 | 142篇 |
2012年 | 243篇 |
2011年 | 272篇 |
2010年 | 140篇 |
2009年 | 150篇 |
2008年 | 229篇 |
2007年 | 224篇 |
2006年 | 193篇 |
2005年 | 199篇 |
2004年 | 214篇 |
2003年 | 182篇 |
2002年 | 183篇 |
2001年 | 39篇 |
2000年 | 30篇 |
1999年 | 49篇 |
1998年 | 35篇 |
1997年 | 42篇 |
1996年 | 31篇 |
1995年 | 17篇 |
1994年 | 13篇 |
1993年 | 12篇 |
1992年 | 13篇 |
1991年 | 13篇 |
1990年 | 8篇 |
1989年 | 16篇 |
1988年 | 10篇 |
1987年 | 17篇 |
1986年 | 8篇 |
1985年 | 21篇 |
1983年 | 10篇 |
1982年 | 12篇 |
1981年 | 9篇 |
1980年 | 9篇 |
1931年 | 11篇 |
1930年 | 9篇 |
1929年 | 7篇 |
1928年 | 8篇 |
1927年 | 7篇 |
1921年 | 7篇 |
1913年 | 7篇 |
排序方式: 共有3762条查询结果,搜索用时 46 毫秒
991.
992.
993.
Höchtl T Geppert A Nürnberg M Unger G Speidl W Wojta J Huber K 《Wiener klinische Wochenschrift》2005,117(23-24):792-800
Unfractionated heparin (UFH) as well as low-molecular-weight heparins (LMWH), especially enoxaparin, are recommended by the current international guidelines for routine used in the conservative treatment of patients with acute coronary syndromes (ACS). UFH is still the recommended antithrombin as soon as percutaneous coronary interventions (PCI) are performed, although the results of different trials clearly have demonstrated the benefit of enoxaparin also in interventional cardiology. Bleeding complications along PCI procedures can be minimized by avoiding crossover from enoxaparin to UFH or vice versa and by reducing the dosage of indirect antithrombins, particularly of enoxaparin, in patients with chronic renal dysfunction and/or the elderly. Especially for those patient groups, bivalirudin offers already today an effective alternative. There is increasing expectation concerning the use of bivalirudin in patients undergoing PCI procedures but firm data exist at present only for low- and medium-risk patients with non ST-elevation ACS. Results of still ongoing trials (ACUITY, HORIZONS) will help to further confirm the role of bivalirudin in patients with high-risk acute coronary syndromes. For other direct antithrombins, e.g., fondaparinux (a pentasaccharide) or melagatran, comparably few data are available at present. Whether these agents will make their way into clinical use, future will tell. 相似文献
994.
995.
An analysis was performed to determine whether a cranial reduction of the portals to the T11/T12 junction instead of the common T10/T11 junction would alter the outcome of patients with stage I seminoma. Of 163 consecutive patients with newly diagnosed testicular seminoma referred to the authors' institution between April 1992 and April 1999, 80 patients with stage I seminoma were treated with cranially reduced para-aortic treatment fields reaching from the top of T12 to the bottom of L4. Median total dose was 20.0 Gy (range, 19.8-27.2 Gy). Patients were followed-up by the use of CT in regular intervals. After a median follow-up of 7.1 years (range, 4.1-11.1 years), four patients (5%) had relapsed resulting in an actuarial 5-year relapse-free survival of 95%. No patients relapsed within the cranially reduced treatment volume above the top of T12. The cranial reduction of the para-aortic treatment fields resulted in a median reduction of treatment volume of 16% (range, 13-21%). The achieved median reduction in treatment volume of 16% appears to be relevant and is not associated with an increased relapse rate. This approach is recommended in analogy to the surgical approach in NSGCT to further minimize the risk of radiation-related late effects. 相似文献
996.
997.
Ramos E Vincenti F Lu WX Shapiro R Trofe J Stratta RJ Jonsson J Randhawa PS Drachenberg CB Papadimitriou JC Weir MR Wali RK 《Transplantation》2004,77(1):131-133
The characteristics and outcome in 10 patients who underwent retransplantation after losing their renal grafts to BK virus-associated nephropathy (BKAN) are described. The patients underwent retransplantation at a mean of 13.3 months after failure of the first graft. Nephroureterectomy of the first graft was performed in seven patients. Maintenance immunosuppression regimens after the first and second grafts were similar, consisting of a combination of a calcineurin inhibitor, mycophenolate mofetil, and prednisone. BKAN recurred in one patient 8 months after retransplantation, but stabilization of graft function was achieved with a decrease in immunosuppression and treatment with low-dose cidofovir. After a mean follow-up of 34.6 months, all patients were found to have good graft function with a mean creatinine of 1.5 mg/dL. From this collective experience from five transplant centers (although the follow-up after retransplantation was not extensive), it can be concluded that patients with graft loss caused by BKAN can safely undergo retransplantation. The risk of recurrence does not seem to be increased in comparison with the first graft. 相似文献
998.
999.
Auer J Berent R Weber T Eber B 《Journal of the American College of Cardiology》2002,40(3):574-5; author reply 575
1000.
Kock N Müller B Vieregge P Pramstaller PP Marder K Abbruzzese G Martinelli P Lang AE Jacobs H Hagenah J Harris J Meija-Santana H Fahn S Hedrich K Kann M Gehlken U Culjkovic B Schwinger E Wszolek ZK Zühlke C Klein C 《Annals of neurology》2002,52(2):257-8; author reply 258